<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="correction"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Drug Investig</journal-id><journal-id journal-id-type="iso-abbrev">Clin Drug Investig</journal-id><journal-title-group><journal-title>Clinical Drug Investigation</journal-title></journal-title-group><issn pub-type="ppub">1173-2563</issn><issn pub-type="epub">1179-1918</issn><publisher><publisher-name>Springer International Publishing AG</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4079516</article-id><article-id pub-id-type="publisher-id">50</article-id><article-id pub-id-type="doi">10.1007/s40261-012-0050-0</article-id><article-categories><subj-group subj-group-type="heading"><subject>Erratum</subject></subj-group></article-categories><title-group><article-title>Erratum to: Bioequivalence and Tolerability Assessment of a Novel Intravenous Ciclosporin Lipid Emulsion Compared to Branded Ciclosporin in Cremophor<sup>&#x000ae;</sup> EL </article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Ehinger</surname><given-names>Karl Henrik Johannes</given-names></name><address><email>johannes.ehinger@neurovive.com</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Hansson</surname><given-names>Magnus Joakim</given-names></name><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Sj&#x000f6;vall</surname><given-names>Fredrik</given-names></name><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Elm&#x000e9;r</surname><given-names>Eskil</given-names></name><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><aff id="Aff1"><label/>NeuroVive Pharmaceutical AB (publ), Medicon Village, 223 81 Lund, Sweden </aff><aff id="Aff2"><label/>Mitochondrial Pathophysiology Unit, Department of Clinical Sciences, Lund University, Lund, Sweden </aff></contrib-group><pub-date pub-type="epub"><day>8</day><month>1</month><year>2013</year></pub-date><pub-date pub-type="ppub"><year>2013</year></pub-date><volume>33</volume><issue>3</issue><fpage>231</fpage><lpage>231</lpage><permissions><copyright-statement>&#x000a9; Springer International Publishing Switzerland 2013</copyright-statement></permissions><related-article related-article-type="corrected-article" id="d30e83" ext-link-type="doi" xlink:href="10.1007/s40261-012-0029-x"/><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer International Publishing Switzerland 2013</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Erratum to: Clin Drug Investig DOI 10.1007/s40261-012-0029-x</title><p>A Published-Ahead-of-Print version of this article was made available online at <ext-link ext-link-type="uri" xlink:href="http://adisonline.com/druginvestigation/toc/publishahead">http://adisonline.com/druginvestigation/toc/publishahead</ext-link> on 28 November 2012. An error was subsequently identified in that version of the article, and the following correction should be noted:</p><p><bold>Section&#x000a0;4, paragraph 6, line 4</bold>, which previously read:</p><p>&#x0201c;Ciclosporin<sup>&#x000ae;</sup> is currently being investigated as pharmacological therapy in patients undergoing intervention treatment after myocardial infarction (the CIRCUS Phase III study, &#x0201c;Cyclosporine and Prognosis in Acute Myocardial Infarction [MI] Patients&#x0201d;, clinicaltrials.gov identifier NCT01502774).&#x0201d;</p><p>Should read:</p><p>&#x0201c;CicloMulsion<sup>&#x000ae;</sup> is currently being investigated as pharmacological therapy in patients undergoing intervention treatment after myocardial infarction (the CIRCUS Phase III study, &#x0201c;Cyclosporine and Prognosis in Acute Myocardial Infarction [MI] Patients&#x0201d;, clinicaltrials.gov identifier NCT01502774).&#x0201d;</p></sec></body><back><fn-group><fn><p>The online version of the original article can be found under doi:10.1007/s40261-012-0029-x.</p></fn></fn-group></back></article>